Interleukin-1 blockade overcomes erlotinib resistance in head and neck squamous cell carcinoma

about

Beyond the Biomarker: Understanding the Diverse Roles of Human Epididymis Protein 4 in the Pathogenesis of Epithelial Ovarian Cancer.A Novel Role for the Interleukin-1 Receptor Axis in Resistance to Anti-EGFR Therapy

P2860

Q54993659-5F7A4B39-B129-4B33-B256-FB2B1B8A6392 Q58693496-72218CFC-C75E-4286-836B-3D3E6B7167C2

P2860

Interleukin-1 blockade overcomes erlotinib resistance in head and neck squamous cell carcinoma

Item

http://www.wikidata.org/entity/Q37689066

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 12 October 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Interleukin-1 blockade overcom ...... d neck squamous cell carcinoma

@en

Interleukin-1 blockade overcom ...... neck squamous cell carcinoma.

@nl

type

Item

label

Interleukin-1 blockade overcom ...... d neck squamous cell carcinoma

@en

Interleukin-1 blockade overcom ...... neck squamous cell carcinoma.

@nl

prefLabel

Interleukin-1 blockade overcom ...... d neck squamous cell carcinoma

@en

Interleukin-1 blockade overcom ...... neck squamous cell carcinoma.

@nl

P1476

Interleukin-1 blockade overcom ...... d neck squamous cell carcinoma

@en

P2093

Aditya Stanam

http://www.w3.org/2001/XMLSchema#string

Laurie Love-Homan

http://www.w3.org/2001/XMLSchema#string

Nnamdi Ihejirika

http://www.w3.org/2001/XMLSchema#string

P2860

Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

IL-1 is required for tumor invasiveness and angiogenesis

Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck.

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.

Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck.

Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck.

Erlotinib-induced skin inflammation is IL-1 mediated in KC-Tie2 mice and human skin organ culture.

An expanding role for interleukin-1 blockade from gout to cancer.

MyD88-Dependent Signaling Decreases the Antitumor Efficacy of Epidermal Growth Factor Receptor Inhibition in Head and Neck Cancer Cells.

P304

76087-76100

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.12590

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Andrean L Simons

Katherine N Gibson-Corley

P577

2016-10-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27738319

http://www.w3.org/2001/XMLSchema#string

P921

head and neck squamous cell carcinoma

interleukin

P932

5342798

http://www.w3.org/2001/XMLSchema#string

Interleukin-1 blockade overcomes erlotinib resistance in head and neck squamous cell carcinoma

about

P2860

P2860

Interleukin-1 blockade overcomes erlotinib resistance in head and neck squamous cell carcinoma

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P921

P932